Clinical Trial and Regulatory Approval Risks: The drug development process is lengthy, expensive, and subject to high failure rates. Imagenebio's product candidates may fail to demonstrate safety or efficacy in clinical trials or may not receive necessary regulatory approvals from agencies like the FDA.

Intense Competition Risks: The biotechnology and pharmaceutical industries are highly competitive. Imagenebio faces competition from numerous companies, including larger, well-established firms with greater resources, which could impact its ability to develop, commercialize, and price its products effectively.

Funding and Capital Raising Risks: Developing novel biotechnologies requires substantial capital investment. Imagenebio may need to raise additional funds in the future, which could lead to dilution of existing shareholders or may not be available on favorable terms, impacting its ability to continue operations.